Gland Pharma Limited — PPTs, 03-11-2025: Investor Presentation

Gland Pharma reported a solid Q2 FY26, with consolidated revenue increasing 6% YoY to ₹1,486.9 Cr and profit (PAT) rising 12% YoY to ₹183.7 Cr. The company's gross profit margin improved to 63%. Strong performance in the US market saw revenue grow 10% YoY to ₹827.9 Cr, while Europe also contributed with 16% YoY growth to ₹284.7 Cr.

Key growth drivers include a focus on complex injectables, with six products launched and three more awaiting approval. The company is aggressively expanding its GLP-1/Pen/cartridge manufacturing capacity from ~40 million to 140 million units, exploring new opportunities. Recent developments include seven new molecule launches in the USA and five ANDA approvals during the quarter. Cenexi's operations, despite a planned shutdown, are progressing with infrastructure upgrades and key product ramp-ups.